中国组织工程研究 ›› 2023, Vol. 27 ›› Issue (15): 2435-2442.doi: 10.12307/2023.612
• 干细胞综述 stem cell review • 上一篇 下一篇
刘东月1,2,3,王宪云2,3,4,王 乐1,2,3,郑明奇1,2,3,尹亚娟1,2,3,杨佳炜1,2,3,丁理妮1,2,3,刘 刚1,2,3
收稿日期:
2022-05-10
接受日期:
2022-08-05
出版日期:
2023-05-28
发布日期:
2022-10-18
通讯作者:
刘刚,博士,主任医师,河北医科大学第一医院心血管内科,河北省石家庄市 050031;河北省结构性心脏病国际联合研究中心,河北省石家庄市 050031;河北省心脏与代谢重点实验室,河北省石家庄市 050031
作者简介:
刘东月,女,1994年生,河北省邢台市人,汉族,河北医科大学在读硕士。
基金资助:
Liu Dongyue1, 2, 3, Wang Xianyun2, 3, 4, Wang Le1, 2, 3, Zheng Mingqi1, 2, 3, Yin Yajuan1, 2, 3, Yang Jiawei1, 2, 3, Ding Lini1, 2, 3, Liu Gang1, 2, 3
Received:
2022-05-10
Accepted:
2022-08-05
Online:
2023-05-28
Published:
2022-10-18
Contact:
Liu Gang, MD, Chief physician, Department of Cardiovascular Medicine, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China; Hebei International Joint Research Center for Structural Heart Disease, Shijiazhuang 050031, Hebei Province, China; Hebei Provincial Key Laboratory of Heart and Metabolism, Shijiazhuang 050031, Hebei Province, China
About author:
Liu Dongyue, Master candidate, Department of Cardiovascular Medicine, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China; Hebei International Joint Research Center for Structural Heart Disease, Shijiazhuang 050031, Hebei Province, China; Hebei Provincial Key Laboratory of Heart and Metabolism, Shijiazhuang 050031, Hebei Province, China
Supported by:
摘要:
文题释义:
外泌体:是细胞外囊泡的一种,粒径大小为30-150 nm,由细胞内的多囊泡体与细胞膜融合后释放到细胞外基质中,广泛存在于细胞培养上清以及各种体液中。
缺血性心脏病:是指冠状动脉发生粥样硬化,从而引起管腔狭窄或闭塞,最终导致心肌缺血坏死而引起的心脏病。
背景:缺血性心脏病是严重威胁人类生命健康的疾病类型之一,而干细胞分泌的外泌体已经在缺血性心脏病的治疗中展示出良好的效果和应用前景,并取得了重要研究进展。
目的:就间充质干细胞外泌体移植治疗缺血性心脏病的疗效、作用机制、优化方案和移植策略分别予以阐述。
方法:第一作者于2021年2月应用计算机在PubMed数据库检索1973年1月至2022年3月相关文献,以“mesenchymal stem cell,exosomes,Ischemic heart disease”为英文检索词,最终纳入英文文献88篇文献进行分析。
结果与结论:①干细胞分泌的外泌体为细胞外囊泡的重要组分之一,是干细胞发挥功能调节的关键组分,且已经在缺血性心脏病方面展示出良好的治疗效果和应用前景。②间充质干细胞分泌的外泌体可促进缺血损伤心肌组织的血管生成和心肌保护作用、抑制心脏纤维化和改善免疫调节等,进而促进心肌修复和心功能改善。③通过基因工程修饰、miRNA修饰、药物或物理条件预处理以及提高外泌体产量等手段可对干细胞外泌体的产量或功能特性等进行优化,以提高其对缺血性心脏病的治疗效果。④利用生物材料运载外泌体、两步递送法、外泌体喷雾技术或细胞膜修饰外泌体等外泌体移植优化策略,可有效提高间充质干细胞外泌体在损伤心肌组织的滞留率,从而增强其对缺血性心脏病的治疗效果。
https://orcid.org/0000-0001-7275-4985 (刘东月);https://orcid.org/0000-0003-1221-3698 (刘刚)
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
中图分类号:
刘东月, 王宪云, 王 乐, 郑明奇, 尹亚娟, 杨佳炜, 丁理妮, 刘 刚. 间充质干细胞外泌体移植治疗缺血性心脏病[J]. 中国组织工程研究, 2023, 27(15): 2435-2442.
Liu Dongyue, Wang Xianyun, Wang Le, Zheng Mingqi, Yin Yajuan, Yang Jiawei, Ding Lini, Liu Gang. Mesenchymal stem cell-derived exosome transplantation for ischemic heart disease[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(15): 2435-2442.
[1] ADAMS RH, ALITALO K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464-478. [2] ARSLAN F, LAI RC, SMEETS MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10(3):301-312. [3] NOORT WA, OERLEMANS MI, ROZEMULLER H, et al. Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. J Cell Mol Med. 2012;16(8):1827-1839. [4] VAN DER SPOEL TI, JANSEN OLS, AGOSTONI P, et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res. 2011;91(4):649-658. [5] JEEVANANTHAM V, BUTLER M, SAAD A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012; 126(5):551-568. [6] WANG X, ZHANG J, ZHANG F, et al. The clinical status of stem cell therapy for ischemic cardiomyopathy. Stem Cells Int. 2015;2015:135023. [7] CHENG L, ZHANG K, WU S, et al. Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy. Stem Cells Int. 2017;2017:6305295. [8] LAI RC, YEO RW, TAN KH, et al. Exosomes for drug delivery -a novel application for the mesenchymal stem cell. Biotechnol Adv. 2013;31(5):543-551. [9] LIANG X, ZHANG L, WANG S, et al. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci. 2016;129(11):2182-2189. [10] VRIJSEN KR, MARING JA, CHAMULEAU SA, et al. Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis via EMMPRIN. Adv Healthc Mater. 2016;5(19):2555-2565. [11] SHAO L, ZHANG Y, LAN B, et al. MiRNA-sequence indicates that mesenchymal stem cells and exosomes have similar mechanism to enhance cardiac repair. Biomed Res Int. 2017;2017:4150705. [12] FISCHER UM, HARTING MT, JIMENEZ F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683-692. [13] FITZNER D, SCHNAARS M, VAN ROSSUM D, et al. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J Cell Sci. 2011;124(Pt 3):447-458. [14] VAN DER POL E, BOING AN, GOOL EL, et al. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost. 2016;14(1):48-56. [15] DENG H, SUN C, SUN Y, et al. Lipid, protein, and microRNA composition within mesenchymal stem cell-derived exosomes. Cell Reprogram. 2018; 20(3):178-186. [16] POWELL S, MCDOUGALL C. Clinical recognition of leprosy: some factors leading to delays in diagnosis. Br Med J. 1974;1(5908):612-613. [17] SLUIJTER JP, VERHAGE V, DEDDENS JC, et al. Microvesicles and exosomes for intracardiac communication. Cardiovasc Res. 2014;102(2):302-311. [18] WANG X, TANG Y, LIU Z, et al. The application potential and advance of mesenchymal stem cell-derived exosomes in myocardial infarction. Stem Cells Int. 2021;2021:5579904. [19] PACHLER K, LENER T, STREIF D, et al. A Good Manufacturing Practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles. Cytotherapy. 2017;19(4):458-472. [20] ANDRIOLO G, PROVASI E, LO CV, et al. Exosomes from human cardiac progenitor cells for therapeutic applications: development of a GMP-grade manufacturing method. Front Physiol. 2018;9:1169. [21] ESCUDIER B, DORVAL T, CHAPUT N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3(1):10. [22] LAMPARSKI HG, METHA-DAMANI A, YAO JY, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods. 2002;270(2):211-226. [23] ZERINGER E, BARTA T, LI M, et al. Strategies for isolation of exosomes. Cold Spring Harb Protoc. 2015;2015(4):319-323. [24] BATRAKOVA EV, KIM MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396-405. [25] SASAKI H, RAY PS, ZHU L, et al. Hypoxia/reoxygenation promotes myocardial angiogenesis via an NF kappa B-dependent mechanism in a rat model of chronic myocardial infarction. J Mol Cell Cardiol. 2001;33(2):283-294. [26] KHAYATI F, PEREZ-CANO L, MAOUCHE K, et al. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. Oncotarget. 2015;6(12):9766-9780. [27] LIANG X, ZHANG L, WANG S, et al. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J Cell Sci. 2016;129(11):2182-2189. [28] XU H, WANG Z, LIU L, et al. Exosomes derived from adipose tissue, bone marrow, and umbilicalcord blood for cardioprotection after myocardial infarction. J Cell Biochem. 2020;121(3):2089-2102. [29] KHAN M, NICKOLOFF E, ABRAMOVA T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015;117(1):52-64. [30] BARILE L, LIONETTI V, CERVIO E, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014;103(4):530-541. [31] GRAY WD, FRENCH KM, GHOSH-CHOUDHARY S, et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res. 2015;116(2): 255-263. [32] KIM H S, CHOI D Y, YUN S J, et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res. 2012;11(2):839-849. [33] ZHU LP, TIAN T, WANG J Y, et al. Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics. 2018;8(22): 6163-6177. [34] SHI B, WANG Y, ZHAO R, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit+ cardiac stem cells from oxidative injury through the PTEN/PI3K/Akt axis. PLoS One. 2018;13(2):e191616. [35] CHEN CH, HSU SY, CHIU CC, et al. MicroRNA-21 mediates the protective effect of cardiomyocyte-derived conditioned medium on ameliorating myocardial infarction in rats. Cells. 2019. doi: 10.3390/cells8080935. [36] PENG Y, ZHAO JL, PENG ZY, et al. Exosomal miR-25-3p from mesenchymal stem cells alleviates myocardial infarction by targeting pro-apoptotic proteins and EZH2. Cell Death Dis. 2020;11(5):317. [37] YU B, KIM HW, GONG M, et al. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int J Cardiol. 2015;182:349-360. [38] CHENG H, CHANG S, XU R, et al. Hypoxia-challenged MSC-derived exosomes deliver miR-210 to attenuate post-infarction cardiac apoptosis. Stem Cell Res Ther. 2020;11(1):224. [39] SONG Y, WANG B, ZHU X, et al. Human umbilical cord blood-derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction mice. Cell Biol Toxicol. 2021;37(1):51-64. [40] WANG Y, ZHAO R, LIU D, et al. Exosomes derived from mir-214-enriched bone marrow-derived mesenchymal stem cells regulate oxidative damage in cardiac stem cells by targeting CaMKII. Oxid Med Cell Longev. 2018;2018:4971261. [41] FERGUSON SW, WANG J, LEE CJ, et al. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep. 2018;8(1):1419. [42] HEFLICH RH, MITTELSTAEDT RA, MANJANATHA MG, et al. DNA sequence analysis of hprt mutations in lymphocytes from Sprague-Dawley rats treated with7, 12-dimethylbenz[a]anthracene. Environ Mol Mutagen. 1996;28(1):5-12. [43] PHILLIPS EN, XIA F, KELSEY KT, et al. Spectra of spontaneous and X-ray-induced mutations at the hprt locus in related human lymphoblast cell lines that express wild-type or mutant p53. Radiat Res. 1995;143(3):255-262. [44] HONG J, WANG Y, HU BC, et al. Transcriptional downregulation of microRNA-19a by ROS production and NF-kappaB deactivation governs resistance to oxidative stress-initiated apoptosis. Oncotarget. 2017;8(41):70967-70981. [45] TIMMERS L, LIM SK, ARSLAN F, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2007;1(2):129-137. [46] HAN C, ZHOU J, LIANG C, et al. Human umbilical cord mesenchymal stem cell derived exosomes encapsulated in functional peptide hydrogels promote cardiac repair. Biomater Sci. 2019;7(7):2920-2933. [47] GU X, LI Y, CHEN K, et al. Exosomes derived from umbilical cord mesenchymal stem cells alleviate viral myocarditis through activating AMPK/mTOR-mediated autophagy flux pathway. J Cell Mol Med. 2020;24(13):7515-7530. [48] GAO J, CHEN X, SHAN C, et al. Autophagy in cardiovascular diseases: role of noncoding RNAs. Mol Ther Nucleic Acids. 2021;23:101-118. [49] SHAO H, YANG L, WANG L, et al. MicroRNA-34a protects myocardial cells against ischemia-reperfusion injury through inhibiting autophagy via regulating TNFalpha expression. Biochem Cell Biol. 2018;96(3):349-354. [50] LI Q, GAO Y, ZHU J, et al. MiR-101 Attenuates myocardial infarction-induced injury by targeting DDIT4 to regulate autophagy. Curr Neurovasc Res. 2020; 17(2):123-130. [51] HUANG Z, WU S, KONG F, et al. MicroRNA-21 protects against cardiac hypoxia/reoxygenation injury by inhibiting excessive autophagy in H9c2 cells via the Akt/mTOR pathway. J Cell Mol Med. 2017;21(3):467-474. [52] DING S, ABUDUPATAER M, ZHOU Z, et al. Histamine deficiency aggravates cardiac injury through miR-206/216b-Atg13 axis-mediated autophagic-dependant apoptosis. Cell Death Dis. 2018;9(6):694. [53] ZHANG C, ZHANG C, WANG H, et al. Effects of miR103a3p on the autophagy and apoptosis of cardiomyocytes by regulating Atg5. Int J Mol Med. 2019; 43(5):1951-1960. [54] ZHAO P, ZHANG B L, LIU K, et al. Overexpression of miR-638 attenuated the effects of hypoxia/reoxygenation treatment on cell viability, cell apoptosis and autophagy by targeting ATG5 in the human cardiomyocytes. Eur Rev Med Pharmacol Sci. 2018;22(23):8462-8471. [55] CHEN G, WANG M, RUAN Z, et al. Mesenchymal stem cell-derived exosomal miR-143-3p suppresses myocardial ischemia-reperfusion injury by regulating autophagy. Life Sci. 2021;280:119742. [56] TALMAN V, RUSKOAHO H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563-581. [57] LUTHER KM, HAAR L, MCGUINNESS M, et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells. J Mol Cell Cardiol. 2018;119: 125-137. [58] FENG Y, HUANG W, WANI M, et al. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One. 2014;9(2):e88685. [59] WANG X, ZHU Y, WU C, et al. Adipose-derived mesenchymal stem cells-derived exosomes carry microRNA-671 to alleviate myocardial infarction through inactivating the TGFBR2/Smad2 axis. Inflammation. 2021;44(5): 1815-1830. [60] MALGULWAR PB, PATHAK P, SINGH M, et al. Downregulation of SMARCB1/INI1 expression in pediatric chordomas correlates with upregulation of miR-671-5p and miR-193a-5p expressions. Brain Tumor Pathol. 2017;34(4):155-159. [61] WEI Z, QIAO S, ZHAO J, et al. miRNA-181a over-expression in mesenchymal stem cell-derived exosomes influenced inflammatory response after myocardial ischemia-reperfusion injury. Life Sci. 2019;232:116632. [62] ZHAO J, LI X, HU J, et al. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res. 2019;115(7):1205-1216. [63] DOMENIS R, CIFU A, QUAGLIA S, et al. Pro inflammatory stimuli enhance the immunosuppressive functions of adipose mesenchymal stem cells-derived exosomes. Sci Rep. 2018;8(1):13325. [64] BURRELLO J, MONTICONE S, GAI C, et al. Stem cell-derived extracellular vesicles and immune-modulation. Front Cell Dev Biol. 2016;4:83. [65] LAI RC, TAN SS, TEH BJ, et al. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. 2012;2012:971907. [66] KANG K, MA R, CAI W, et al. Exosomes secreted from CXCR4 overexpressing mesenchymal stem cells promote cardioprotection via akt signaling pathway following myocardial infarction. Stem Cells Int. 2015;2015:659890. [67] WANG X, CHEN Y, ZHAO Z, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction. J Am Heart Assoc. 2018;7(15):e8737. [68] NI J, LIU X, YIN Y, et al. Exosomes derived from timp2-modified human umbilical cord mesenchymal stem cells enhance the repair effect in rat model with myocardial infarction possibly by the Akt/Sfrp2 pathway. Oxid Med Cell Longev. 2019;2019:1958941. [69] CHEN Y, ZHAO Y, CHEN W, et al. MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction. Stem Cell Res Ther. 2017;8(1):268. [70] SEO HH, LEE SY, LEE CY, et al. Exogenous miRNA-146a enhances the therapeutic efficacy of human mesenchymal stem cells by increasing vascular endothelial growth factor secretion in the ischemia/reperfusion-injured heart. J Vasc Res. 2017;54(2):100-108. [71] HUANG P, WANG L, LI Q, et al. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovasc Res. 2020;116(2):353-367. [72] ZHU LP, TIAN T, WANG JY, et al. Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction. Theranostics. 2018;8(22):6163-6177. [73] XU R, ZHANG F, CHAI R, et al. Exosomes derived from pro-inflammatory bone marrow-derived mesenchymal stem cells reduce inflammation and myocardial injury via mediating macrophage polarization. J Cell Mol Med. 2019;23(11):7617-7631. [74] PARK DJ, YUN WS, KIM WC, et al. Improvement of stem cell-derived exosome release efficiency by surface-modified nanoparticles. J Nanobiotechnology. 2020;18(1):178. [75] STEPHANOPOULOS N, ORTONY JH, STUPP SI. Self-Assembly for the Synthesis of Functional Biomaterials. Acta Mater. 2013;61(3):912-930. [76] WANG J, BONACQUISTI EE, BROWN AD, et al. Boosting the Biogenesis and Secretion of Mesenchymal Stem Cell-Derived Exosomes. Cells. 2020. doi: 10.3390/cells9030660. [77] CHEN CW, WANG LL, ZAMAN S, et al. Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction. Cardiovasc Res. 2018;114(7):1029-1040. [78] LIU S, CHEN X, BAO L, et al. Treatment of infarcted heart tissue via the capture and local delivery of circulating exosomes through antibody-conjugated magnetic nanoparticles. Nat Biomed Eng. 2020;4(11):1063-1075. [79] WEI G, JIE Y, HAIBO L, et al. Dendritic cells derived exosomes migration to spleen and induction of inflammation are regulated by CCR7. Sci Rep. 2017;7:42996. [80] RODRIGUEZ PL, HARADA T, CHRISTIAN DA, et al. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science. 2013;339(6122):971-975. [81] VRIJSEN KR, MARING JA, CHAMULEAU SA, et al. Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis via EMMPRIN. Adv Healthc Mater. 2016;5(19):2555-2565. [82] YAO J, HUANG K, ZHU D, et al. A minimally invasive exosome spray repairs heart after myocardial infarction. ACS Nano. 2021. doi: 10.1021/acsnano.1c00628. [83] ZHANG N, SONG Y, HUANG Z, et al. Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model. Biomaterials. 2020;255:120168. [84] NIESWANDT B, WATSON SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449-461. [85] BUTLER LM, METSON-SCOTT T, FELIX J, et al. Sequential adhesion of platelets and leukocytes from flowing whole blood onto a collagen-coated surface: requirement for a GpVI-binding site in collagen. Thromb Haemost. 2007;97(5):814-821. [86] HU CM, FANG RH, WANG KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526(7571):118-121. [87] ANDERSON JD, JOHANSSON HJ, GRAHAM CS, et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappab signaling. Stem Cells. 2016;34(3):601-613. [88] LENER T, GIMONA M, AIGNER L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles. 2015;4:30087. |
[1] | 农复香, 蒋志雄, 李英豪, 许文聪, 施智兰, 罗 慧, 张晴朗, 钟 爽, 唐梅文. 外泌体调控铁死亡在疾病诊断治疗中的应用与作用[J]. 中国组织工程研究, 2023, 27(在线): 1-10. |
[2] | 潘钟杰, 秦志鸿, 郑铁军, 丁晓飞, 廖世杰. 股骨头坏死发病机制中非编码RNA的靶标性[J]. 中国组织工程研究, 2023, 27(9): 1441-1447. |
[3] | 党 祎, 杜成砚, 姚红林, 袁能华, 曹 金, 熊 山, 张顶梅, 王 信. 激素型骨坏死与氧化应激[J]. 中国组织工程研究, 2023, 27(9): 1469-1476. |
[4] | 许 言, 李 平, 赖春花, 朱培君, 杨 烁, 徐淑兰. 血管化骨再生中压电生物材料的应用[J]. 中国组织工程研究, 2023, 27(7): 1126-1132. |
[5] | 薛 婷, 张新日, 孔晓梅. 纳米材料多模态显像示踪技术在间充质干细胞治疗尘肺中的应用[J]. 中国组织工程研究, 2023, 27(7): 1133-1140. |
[6] | 李启程, 邓 进, 付小洋, 韩 娜. 骨髓间充质干细胞来源外泌体对成肌细胞缺氧状态的影响[J]. 中国组织工程研究, 2023, 27(6): 853-859. |
[7] | 王 敏, 尹秀山, 王盈熹, 张 妍, 赵 龙, 夏书月. 吸入骨髓间充质干细胞来源外泌体减轻慢性阻塞性肺疾病的炎性损伤[J]. 中国组织工程研究, 2023, 27(6): 827-834. |
[8] | 张厚君, 邓博文, 蒋昇源, 赵 毅, 任敬佩, 徐 林, 穆晓红. 脑性瘫痪儿童脑脊液内外泌体的蛋白质组学分析[J]. 中国组织工程研究, 2023, 27(6): 903-908. |
[9] | 高 婷, 马小红, 李晓荣. 三种不同来源卵巢颗粒细胞外泌体的提取及鉴定[J]. 中国组织工程研究, 2023, 27(6): 860-865. |
[10] | 黄贵江, 季雨伟, 赵 鑫, 杨 艺, 赵玉兰, 王佩锦, 唐 薇, 角建林. 胎盘间充质干细胞不同给药途径治疗骨质疏松性骨折树鼩的疗效和机制[J]. 中国组织工程研究, 2023, 27(6): 909-914. |
[11] | 张岐剑, 徐希明. 外胚层间充质干细胞的获取及应用[J]. 中国组织工程研究, 2023, 27(6): 928-934. |
[12] | 袁 博, 谢利德, 付秀美. 许旺细胞源性外泌体促进损伤周围神经的修复与再生[J]. 中国组织工程研究, 2023, 27(6): 935-940. |
[13] | 熊 娟, 关亚琳, 杨雨童, 王 矾, 刘忠山. 干细胞在皮肤抗衰老中的应用[J]. 中国组织工程研究, 2023, 27(6): 948-954. |
[14] | 许其静, 杨伊春, 雷 微, 杨 莹, 余 江, 夏婷婷, 张 萌, 章 涛, 张 潜. 糖尿病皮肤慢性创面无细胞治疗的进展与问题[J]. 中国组织工程研究, 2023, 27(6): 962-969. |
[15] | 陈冠廷, 张琳琪, 李清茹. 外泌体miRNA对慢性肾脏病诊断价值的Meta分析[J]. 中国组织工程研究, 2023, 27(6): 970-976. |
1.1.7 检索策略 PubMed数据库检索策略,见图1。
1.1.8 检索文献量 初步共检索到文献1 560篇,均为英文文献。
文题释义:#br# 外泌体:是细胞外囊泡的一种,粒径大小为30-150 nm,由细胞内的多囊泡体与细胞膜融合后释放到细胞外基质中,广泛存在于细胞培养上清以及各种体液中。#br# 缺血性心脏病:是指冠状动脉发生粥样硬化,从而引起管腔狭窄或闭塞,最终导致心肌缺血坏死而引起的心脏病。#br# 中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
缺血性心脏病是指冠状动脉发生粥样硬化,从而引起管腔狭窄或闭塞,最终导致心肌缺血坏死而引起的心脏病,简称冠心病。目前,缺血性心脏病仍然是世界范围内主要死因,虽然临床上的经皮冠状动脉植入术和冠状动脉旁路移植术可迅速恢复心肌供血,但并不能阻止动脉粥样硬化的进展,且术后并发症还会加重心肌损伤。随着再生医学技术的不断发展,间充质干细胞在治疗缺血性心脏病方面发挥着重要作用,具有独特优势。间充质干细胞是指从人体组织中分离出来的、具有多向分化潜能和免疫调节特性的一类多能干细胞。许多研究已证明间充质干细胞治疗缺血性心脏病的可行性、安全性和有效性,但因受间充质干细胞种类、移植方法与剂量、移植后归巢率和存活率等问题的影响使其疗效仍未能充分发挥。
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||